6 June 2024
TECHNOLOGICAL FRONTIER
Significant technological advances in the diagnosis, treatment and monitoring of demyelinating diseases
15:00h – 16:00h | Registration and collection of credentials
16:00h – 16:20h | Welcome
16:20 – 17:45 | Presentations
- Mercedes Lachén: ‘Neuroproteomics: opportunities, challenges and clinical potential’
- Silvia de Santis: ‘Non invasive MRI-based biomarkers to detect and characterize axonal pathology in early multiple sclerosis patients’
- Julián Isla: ‘AI: No data, no money’
17:45h | Coffee Break
18:05h | Round table
Opportunities that new technologies bring to science and the clinic. The panel will seek to answer the questions: Do they meet the real needs of scientists, physicians and patients? What is needed to develop their potential?
19:00-20:00h |Invited lecture
- Gabriel Lepousez: ‘New perspectives in body-brain communications: how peripheral macrophages and gut microbiota-derived signals reach the brain’
7 June 2024
SCIENTIFIC FRONTIER
Advances in knowledge
10:00h – 11:00h | Presentations
- Emilio Geijo-Barrientos: ‘Myelin and neuronal function: the neurobiology of demyelination problems’
- Francisco Carratalá: ‘Red flags in the early clinical detection of demyelinating diseases in children’
11:00h – 11:30h | Coffee Break / Posters
11:30h – 13:00h | Presentations
- Federico Pallardó: ‘Role of calcium in demyelinating diseases’
- Salvador Martínez: ‘Cellular therapy in congenital demyelinating disorders’
- Fernando de Castro: ‘Future of scientific investigation on neurodegenerative diseases’
13:00h – 15:00h | Lunch / Posters
15:00h – 16:30h | Round table
- Introductory guest lecture José María Moraleda: ‘TERAV network seeks new therapeutic solutions’
The panel will seek to answer the questions: Are scientific efforts meeting clinical demands? Which pathogenic fields require more effort to understand the underlying mechanisms? What are scientists asking of patients? What are patients asking of scientists? All this with the aim of enhancing translatability and new scientific approaches based on clinical needs.
16:30h – 17:00h | Coffee Break
17:00h – 18:00h | Invited lecture
- Dr. Paul Orchard: ‘Cellular Therapy for Disorders Affecting the Nervous System’
20:00h | Congress dinner at Yimby Bilbao space
8 June 2024
CLINICAL FRONTIER
Advances on therapies
9:30h – 11:00h | Presentations
- Marc Engelen: Adrenoleukodystrophy (ALD). ‘From axonal degeneration to clinical trials’.
- Nathalie Cartier: ‘Our experience on gene therapies on leukodystrophies’
- Verónica Cantarín and Inés Solís: ‘Our experience with intrathecal cellular therapies with mesenchymal cells in childhood cerebral X-linked adrenoleukodystrophy’
11:00 – 11:30 | Coffee Break
11:30h – 12:40h | Presentations
- Sara García Gil Perotin: ‘Autologous hematopoietic precursor transplantation on multiple sclerosis: our experience and new perspectives’
- Ane Fullaondo: ‘Value-based medicine’
- Pedro Carrascal: ‘The patients’ perspective in relation to the scientific and clinical process’
12:40h – 13:40h | Round table
Technological, scientific, clinical and patient studies on the regulation and legality for the promotion of clinical trials and personalized therapies. Physicians need to know the mechanisms of action and availability of objective biomarkers of disease progression. Scientists need clinical studies that are actually feasible. Patients’ perspective on the therapeutic process, scientific evolution and dynamics of clinical trials.
13:40h – 14:00h | Synthesis – Acknowledgments
6 June 2024
TECHNOLOGICAL FRONTIER
Significant technological advances in the diagnosis, treatment and monitoring of demyelinating diseases
15:00h – 16:00h | Registration and collection of credentials
16:00h – 16:20h | Welcome
16:20 – 17:45 | Presentations
- Mercedes Lachén: ‘Neuroproteomics: opportunities, challenges and clinical potential’
- Silvia de Santis: ‘Non invasive MRI-based biomarkers to detect and characterize axonal pathology in early multiple sclerosis patients’
- Julián Isla: ‘AI: No data, no money’
17:45h | Coffee Break
18:05h | Round table
Opportunities that new technologies bring to science and the clinic. The panel will seek to answer the questions: Do they meet the real needs of scientists, physicians and patients? What is needed to develop their potential?
19:00-20:00h |Invited lecture
- Gabriel Lepousez: ‘New perspectives in body-brain communications: how peripheral macrophages and gut microbiota-derived signals reach the brain’
7 June 2024
SCIENTIFIC FRONTIER
Advances in knowledge
10:00h – 11:00h | Presentations
- Emilio Geijo-Barrientos: ‘Myelin and neuronal function: the neurobiology of demyelination problems’
- Francisco Carratalá: ‘Red flags in the early clinical detection of demyelinating diseases in children’
11:00h – 11:30h | Coffee Break / Posters
11:30h – 13:00h | Presentations
- Federico Pallardó: ‘Role of calcium in demyelinating diseases’
- Salvador Martínez: ‘Cellular therapy in congenital demyelinating disorders’
- Fernando de Castro: ‘Future of scientific investigation on neurodegenerative diseases’
13:00h – 15:00h | Lunch / Posters
15:00h – 16:30h | Round table
- Introductory guest lecture José María Moraleda: ‘TERAV network seeks new therapeutic solutions’
The panel will seek to answer the questions: Are scientific efforts meeting clinical demands? Which pathogenic fields require more effort to understand the underlying mechanisms? What are scientists asking of patients? What are patients asking of scientists? All this with the aim of enhancing translatability and new scientific approaches based on clinical needs.
16:30h – 17:00h | Coffee Break
17:00h – 18:00h | Invited lecture
- Dr. Paul Orchard: ‘Cellular Therapy for Disorders Affecting the Nervous System’
20:00h | Congress dinner at Yimby Bilbao space
8 June 2024
CLINICAL FRONTIER
Advances on therapies
9:30h – 11:00h | Presentations
- Marc Engelen: Adrenoleukodystrophy (ALD). ‘From axonal degeneration to clinical trials’.
- Nathalie Cartier: ‘Our experience on gene therapies on leukodystrophies’
- Verónica Cantarín and Inés Solís: ‘Our experience with intrathecal cellular therapies with mesenchymal cells in childhood cerebral X-linked adrenoleukodystrophy’
11:00 – 11:30 | Coffee Break
11:30h – 12:40h | Presentations
- Sara García Gil Perotin: ‘Autologous hematopoietic precursor transplantation on multiple sclerosis: our experience and new perspectives’
- Ane Fullaondo: ‘Value-based medicine’
- Pedro Carrascal: ‘The patients’ perspective in relation to the scientific and clinical process’
12:40h – 13:40h | Round table
Technological, scientific, clinical and patient studies on the regulation and legality for the promotion of clinical trials and personalized therapies. Physicians need to know the mechanisms of action and availability of objective biomarkers of disease progression. Scientists need clinical studies that are actually feasible. Patients’ perspective on the therapeutic process, scientific evolution and dynamics of clinical trials.
13:40h – 14:00h | Synthesis – Acknowledgments
SPEAKERS
Ane Fullaondo
With a degree in Biology and a PhD in Genetics, she decided to make the leap from the laboratory to management. After seven years dedicated exclusively to basic science, she joined the Biosistemak project (Research Center on Chronicity of the Basque Country, an international benchmark in the study and analysis of the chronically ill) in 2013. She is currently the scientific director of Biosistemak.
Emilio Geijo Barrientos
Professor of Physiology at the Faculty of Medicine of the UMH. Researcher at the Institute of Neurosciences as principal investigator of the Research Group: Neurobiology of mental, neurodegenerative and neuro-oncological diseases. International leader in electrophysiological studies of cortical circuits.
Federico Pallardó
Member of the CIBERER steering committee (responsible for training), he directs the CIBERER-Biobank of the ISCIII. and expert in neurodegenerative diseases. He is currently a professor at the University of Valencia, being dean of the Faculty of Medicine and Dentistry of the University of Valencia between 2011 and 2017. He has been a visiting professor at the Chicago Medical School. He has been director of the Central Research Unit, coordinating the basic research laboratories of INCLIVA for more than ten years. He is group leader of the CIBER in its rare diseases division since 2007.
Fernando de Castro
Senior Scientist of the CSIC and Principal Investigator of the Developmental Neurobiology Group-GNDe at the Cajal Institute-CSIC. His main research interests range from oligodendrogliogenesis and myelination to the pathophysiology of demyelinating diseases (multiple sclerosis, leukodystrophies) and the search for cellular and molecular mechanisms to effectively (re)myelinate. Current president of the Spanish Glial Network
Francisco Carratalá
Neuropediatrician at the Hospital Universitario San Juan de Alicante for 29 years and the first neurologist member of the European Neuropediatric Society (EPNS)
Gabriel Lepousez
D. in Neuroscience from the Pierre & Marie Curie University of Paris and researcher at the Pasteur Institute, in the Perception and Memory Unit. His research focuses on brain plasticity and circuit mechanisms underlying sensory perception and memory.
Inés Solís
A medical specialist in Radiodiagnosis, she has been working at the Hospital Infantil Universitario Niño Jesús in Madrid since 2008. In recent years, she has focused her dedication to the field of Paediatric Neuroradiology, with special interest in leukodystrophies.
José María Moraleda
Coordinator of the Spanish network of advanced therapies (TERAV), for 11 years head of the Hematology Service and the Hematopoietic Transplant and Cell Therapy Unit of the Virgen de la Arrixaca University Hospital in Murcia, professor at the University of Murcia and president of the Spanish Society of Hematology and Hemotherapy (SEHH) (2013-2016)
Julián Isla
Software engineer at Microsoft, advisor to the European Medicines Agency and member of the 29 Foundation, father of a son affected by a neurodegenerative disease who carries out an important international activity to promote the use of AI and other technologies for the diagnosis and cure of these diseases
Marc Engelen
He is currently working in the Department of Pediatric Neurology and specifically in the center for white matter disorders at the VU University Medical Center (UMC), Amsterdam. Marc has an intense research activity in leukodystrophies, especially in adrenoleukodystrophy.
Mercedes Lachén
Navarra BIOMED researcher specialist in proteomics in neurodegenerative diseases
Nathalie Cartier
Director of the INSERM lab NeuroGenCell (Gene and cell Therapy for neurodegenerative diseases of adults and children) at the Paris Brain Institute (ICM) at the Pitié Salpêtrière Hospital in Paris. She acted as an investigator in the framework of the first gene therapy developed (in X-ALD) and her group is actively working on the development of gene therapies in neurodegenerative diseases. Recent awards: Grand Prix de la Fondation pour la Recherche médicale (2019), Grand prix de l’Académie des Sciences 2019.
Paul Orchard
Medical Director of the Inherited Metabolic and Storage Diseases Program and Professor in the Department of Pediatrics, Division of Cell Therapy and Blood and Marrow Transplantation at the University of Minnesota Hospital. Dr. Orchard’s focus is on the use of hematopoietic stem cell transplantation and other cell therapies for inherited metabolic disorders, with special interest in inherited leukodystrophies, mucopolysaccharidoses and osteopetrosis. His clinical research focuses on the evolution of novel and combination therapies to decrease toxicity and improve outcomes, with special interest in the use of gene therapy approaches, with extensive experience in leukodystrophies.
Pedro Carrascal
Current General Director of the Patients’ Organizations Platform (POP). Director of ADEMBI (Multiple Sclerosis Association of Bizkaia) for 25 years (until 2022), as well as Esclerosis Múltiple Euskadi and Esclerosis Múltiple España, positions he held simultaneously during those years.
Salvador Martínez
Director of the Instituto Neurociencias de Alicante (IN), UMH-CSIC (April 2016-November 2020), Professor of Human Anatomy Medicine Univ. Murcia and UMH (since 2004), Professor of the Master of IN (since 2004) and Pasteur Institute of Paris (since 2005), Full Professor and Professor of the Universities of Murcia and Miguel Hernández de Elche
Sara García Gil-Perotin
Neurologist at La Fe Hospital in Valencia and in charge of the follow-up and registry of MS patients transplanted with bone marrow progenitors, as a member of the ADWP of the EBMT
Silvia de Santis
Principal Researcher at the Institute of Neurosciences (CSIC-UMH), San Juan de Alicante
Verónica Cantarín
Exclusive dedication to neuropediatrics since 2009, PhD in 2021 with outstanding “Cum Lauden” by the Autonomous University of Madrid. In recent years I have focused my interest in the field of neuroimmunology and acquired brain injury where she carries out several research projects. Head of the CLINICAL GROUP GV23/ER/3 of the Center for Biomedical Research Network for Rare Diseases (CIBERER)-Instituto de Salud Carlos III.
Scientific Congress | Registration for all 3 days
Includes
- Congress Material
- Admission to all sessions and poster areas
- Coffee breaks
- Picnic Lunch on June 7
- Picnic dinner on June 7
- Certificate of attendance (online submission)
Includes
- Congress Material
- Admission to all sessions and poster areas
- Coffee breaks
- Picnic Lunch on June 7
- Picnic dinner on June 7
- Certificate of attendance (online submission)
Scientific Congress | Registration by days
Includes
- Congress Material
- Attendance at the conferences, exhibition area and posters on June 6
- Coffee breaks
- Certificate of attendance (online submission)
Includes
- Congress Material
- Attendance to the conferences, exhibition area and posters on June 7
- Coffee breaks
- Picnic Lunch on June 7
- Picnic dinner on June 7
- Certificate of attendance (online submission)
Includes
- Congress Material
- Attendance to the conferences, exhibition area and posters on June 7
- Coffee breaks
- Certificate of attendance (online submission)
Includes
- Congress Material
- Attendance to the conferences, exhibition area and posters on June 7
- Coffee breaks
- Picnic Lunch on June 7
- Picnic dinner on June 7
- Certificate of attendance (online submission)
Includes
- Congress Material
- Attendance to the conferences, exhibition area and posters on June 7
- Coffee breaks
- Certificate of attendance (online submission)
Includes
- Congress Material
- Attendance to the conferences, exhibition area and posters on June 8
- Coffee breaks
- Certificate of attendance (online submission)